Antiproliferative effects of interleukin-12 treatment on human tumor colony-forming units taken directly from patients

Anti-Cancer Drugs

Volumn 7, Issue 3, 1996, Pages 275-280

  Izquierdo, Miguel A ^a,b   Degen, Donna ^a   Sypek, Joseph P ^a   Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

^b PFIZER INC   (United States)

Author keywords

Cloning assay; Cytokines; Interleukin 12; Natural killer cell stimulatory factor

Indexed keywords

INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 12;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; TUMOR CELL;

EID: 0030008336     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199605000-00006     Document Type: Article

References (37)

1. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989; 170: 827-45.
2. Stern AS, Podlaski FJ, Hulmes JD, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lympho-blastoid cells. Proc Natl Acad Sci USA 1990; 87: 6808-12.
3. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effect on T and natural killer cells. J Immunol 1990; 146: 3074-81.
4. Gubler U, Chua AO, Schoenhout DS, et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991; 88: 4143-7.
5. Schoenhaut DS, Chua AO, Wolitzky AG, et al. Cloning and expression of murine IL-12. J Immunol 1992; 148: 3433-40.
6. D'Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (NKSF/IL-12) by peripheral blood mononuclear cells. J Exp Med 1992; 176: 1387-98.
7. Robertson MJ, Soiffer RJ, Wolf SF, et al. Responses of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 1992; 175: 779-88.
8. + NK cells. J Immunol 1992; 148: 2429-36.
9. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R. Regulation of human cytolitic lymphocyte responses by interleukin-12. Cell Immunol 1992; 143: 127-42.
10. Gatelty MK, Desai B, Wolitzky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991; 147: 874-82.
11. + T lymphocytes, and NK cells. J Immunol 1992; 149: 3495-502.
12. Chan SH, Perussia B, Gupta JW, et al. Induction of interferon-y production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991; 173: 869-79.
13. Aste-Amezaga M, D'Andrea A, Kubin M, Trinchieri G. Cooperation of natural killer all stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol 1994; 156: 480-92.
14. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin-12 [IL-12]) induces T helper type 1 (Th1)-specific immune response and inhibits the development of IL-4 producing Th cells. J Exp Med 1991; 177: 1199-204.
15. +T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547-9.
16. +T cells to enhance priming for interferon-y production and diminishes IL-4 inhibition of such priming. Proc Natl Acad Sci USA 1993; 90: 10188-92.
17. Kennedy MK, Picha KS, Shanebeck KD, Anderson DM, Grabstein KH. Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones. Eur J Immunol 1994; 24: 2271-8.
18. Gately MK, Warrier RR, Honasoge S, et al. Administration of IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 1994; 6: 157-67.
19. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223-30.
20. Nastala CL, Edington H, Storkus W, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994; 153: 1697-706.
21. Tahara H, Zeh HJ, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54; 182-9.
22. Hill LL, Perussia B, McCue PA, Korngold R. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. Cancer Res 1994; 54: 763-70.
23. Lieberman MD, Sigal RK, Williams NN, Daly JM. Natural killer cell stimulatory factor (NKSF) augments natural killer cell and antibody-dependent tumoricidal response against colon carcinoma cell lines. J Surg Res 1991; 50: 410-5.
24. Soiffer RJ, Robertson MJ, Murray C, Cochran K, Ritz. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematological and solid malignancies. Blood 1993; 82: 2790-6.
25. Rossi AR, Pericle F, Rashleigh S, Janiec J, Djeu JY. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994; 83; 1323-8.
26. Herberman RB, Odlham RK. Problems associated with study of cell-mediated immunity to human tumors by microcytotoxicity assays. J Natl Cancer Inst 1975; 55: 749-53.
27. Bradley EC, Catino JJ, Issell BF, et al. Cell-mediated inhibition of tumor colony formation in agarose by resting and interleukin 2-stimulated human lymphocytes. Cancer Res 1985; 45: 1464-8.
28. Saito T, Berens ME, Welander CE. Direct and indirect effects of human recombinant y-interferon on tumor cells in a clonogenic assay. Cancer Res 1986; 46: 1142-7.
29. Von Hoff DD, Forseth BJ, Huong M, Buchok JB, Lathan B. Improved plating efficiencies for human tumors cloned in capillary tubes versus Petri dishes. Cancer Res 1986; 46: 4012-7.
30. J6Q. Von Hoff DD, Sandbach JF, Clark G, et al. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician, y Natl Cancer Inst 1990; 82: 110-16.
31. Hanauske U, Hanauske AR, Marshall MH, Muggia VA, Von Hoff DD. Biphasic effects of vanadium salts on in vitro tumor colony growth. Int J Cell Cloning 1987; 5: 170-8.
32. Shoemaker RH, Wolpert-DeFilippes MK, Kern DH, et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res 1985; 45: 2145-53.
33. Bree AG, Schlerman FJ, Kaviani MD, Hastings RC, Hitz SL, Goldman SJ. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem Biophys Res Commun 1994; 204: 1150-7.
34. Sarmiento UM, Riley JH, Knaak PA, et al. Biological effects of recombinant human interleukin-12 in suirrel monkeys (Sciureus saimiri). Lab Invest 1994; 71: 862-73.
35. Allavena PA, Paganin C, Zhou D, Bianchi G, Sozzani S, Mantovani A. Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium. Blood 1994; 84: 2261-8.
36. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-6.
37. Foulke RS, Marshall MH, Trotta PP, Von Hoff DD. In vitro assessment of the effects of granulocyte-macrophage colony-stimulating factor on primary human tumors and derived lines. Cancer Res 1990; 50: 6264-7.